<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nichols, Emma Hitt</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Wang-Gillam, Andrea</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">MM-398 Plus 5-FU and LV Extend OS and PFS in mPAC</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-10-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">10-11</style></pages><abstract><style  face="normal" font="default" size="100%">The addition of MM-398 to 5-flurouracil (5-FU) and leucovorin (LV) extended overall survival and progression-free survival in patients with metastatic pancreatic adenocarcinoma who had previously received gemcitabine-based treatment when compared with 5-FU plus LV alone. This article presents data from the Study of MM-398 With or Without 5-Fluorouracil and Leucovorin, Versus 5-Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer [NAPOLI 1; Von Hoff D et al. Ann Oncol. 2014 (abstr O-0003)].</style></abstract><number><style face="normal" font="default" size="100%">22</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>